# Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

> **NCT02386098** · PHASE2 · TERMINATED · sponsor: **ViiV Healthcare** · enrollment: 86 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** BMS-955176
- **DRUG:** Atazanavir (ATV)
- **DRUG:** Ritonavir (RTV)
- **DRUG:** Dolutegravir (DTG)
- **DRUG:** Tenofovir (TDF)

## Key facts

- **NCT ID:** NCT02386098
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-08
- **Primary completion:** 2017-06-07
- **Final completion:** 2017-06-07
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** GI Intolerability
- **Last updated:** 2018-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386098, "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02386098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*